Tipiracil is an inhibitor of thymidine phosphorylas, and it prevents the metabolism of trifluoridine leading to its increased bioavailability.
It has antiangiogenic properties, as well.
In combination with Trifluridine, it is approved for use in patients with metastatic colorectal cancer.